C4 Therapeutics (CCCC) Insider Steven Hoerter Buys 62,000 Shares
Steven Hoerter purchased 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026, reflecting confidence in the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Hoerter bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- Steven Hoerter bought 62,000 shares of C4 Therapeutics, Inc. for an undisclosed value on June 24, 2026.
- The stock is currently trading at $4.26, up from a previous close of $3.39, indicating positive momentum.
- Analysts have set a target mean price of $13.33, with JP Morgan initiating coverage at an Overweight rating on October 9, 2026.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at C4 Therapeutics, Inc.
On June 24, 2026, Steven Hoerter bought 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC). The total value of the transaction was not disclosed. This purchase reflects a growing confidence in the company's future as it develops innovative therapies.
Other Insiders Join in the Purchase
On the same day, several other insiders made similar moves. Ronald Cooper, Utpal Koppikar, Grogan Donna Roy, Owen Hughes, Stephen Fawell, and Laura Bessen each acquired 62,000 shares. This coordinated buying suggests a strong belief among the leadership in C4 Therapeutics' potential.
How C4 Therapeutics, Inc. Stock Has Traded
C4 Therapeutics' stock is currently trading at $4.26, showing an increase from its previous close of $3.39. The shares are positioned well above its 52-week low of $1.69 and are nearing its 52-week high of $5.17. The stock's performance may reflect investor optimism as the company advances its clinical-stage projects.
Analysts Set New Price Targets
Analysts have a positive outlook for C4 Therapeutics. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and a price target of $10. The consensus price target among analysts is $13.33, based on six opinions, suggesting confidence in the company’s growth trajectory.
About C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing novel therapies that degrade disease-causing proteins, with promising candidates aimed at treating conditions like multiple myeloma and non-small cell lung cancer.
What's Ahead for C4 Therapeutics, Inc.
Investors will be watching for the next earnings report scheduled for November 5, 2026. This insider activity, combined with the upcoming earnings, will be key indicators of the company's direction. The current insider buying trend reflects a commitment to the company's innovative approach in the healthcare sector.
Related Filing Alerts
Source: Steven Hoerter's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts